The North America T-Cell therapy Market should witness market growth of 16.1% CAGR during the forecast period (2023-2030).
T-cell therapy, sometimes called adoptive cell transfer therapy, is a cutting-edge and individualized type of immunotherapy that uses a patient's natural immune system to target and eradicate cancer cells or other disorders. It entails taking T-cells, a white blood cell, out of the patient's body and altering them in a lab so they can better recognize and kill disease targets or cancer cells. The patient's body is then reinfused with a significant amount of these enlarged, modified T-cells. T-cell therapy provides a potentially efficient and accurate therapeutic alternative by assisting in the immune response's augmentation against the targeted disease.
The primary factors driving the expansion of the market are the rise in cancer prevalence, the aging population, and the increasing usage of multiple-cell therapy approaches for alleviating the symptoms of cancer. Cancers like leukemia, lymphoma, cancer relapse, and myeloma are among those on the rise, raising the need for efficient treatments. In order to make sure that their social and health systems are prepared to capitalize on this demographic transformation, all nations face significant hurdles.
The high demand for the product in this region has been largely ascribed to the region's robust research, commercial basis, and the significant number of clinical trials being conducted for T-cell treatments. The adoption of these therapies has also been hastened, leading to significant market growth due to the rising number of approvals from regulators in Canada and the US, as well as the region's shifting reimbursement environment. Additionally, the rising prevalence of chronic illnesses like cancer and autoimmune diseases and the presence of well-established and powerful market competitors are the main factors for intensive R&D in this region. Thus, the market in North America is anticipated to grow throughout the forecast period due to an increase in cancer incidence and the expansion of clinical trials in T-Cell therapies.
The US market dominated the North America T-Cell therapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2,375.5 million by 2030. The Canada market is poised to grow at a CAGR of 18.8% during (2023-2030). Additionally, The Mexico market should witness a CAGR of 17.7% during (2023-2030).
Based on End-user, the market is segmented into Hospitals and Cancer Treatment Centers. Based on Indication, the market is segmented into Lymphoma, Acute Lymphocytic Leukemia and Others. Based on Therapy Type, the market is segmented into CAR T-Cell Therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others) and T-Cell Receptor (TCR)-Based. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
T-cell therapy, sometimes called adoptive cell transfer therapy, is a cutting-edge and individualized type of immunotherapy that uses a patient's natural immune system to target and eradicate cancer cells or other disorders. It entails taking T-cells, a white blood cell, out of the patient's body and altering them in a lab so they can better recognize and kill disease targets or cancer cells. The patient's body is then reinfused with a significant amount of these enlarged, modified T-cells. T-cell therapy provides a potentially efficient and accurate therapeutic alternative by assisting in the immune response's augmentation against the targeted disease.
The primary factors driving the expansion of the market are the rise in cancer prevalence, the aging population, and the increasing usage of multiple-cell therapy approaches for alleviating the symptoms of cancer. Cancers like leukemia, lymphoma, cancer relapse, and myeloma are among those on the rise, raising the need for efficient treatments. In order to make sure that their social and health systems are prepared to capitalize on this demographic transformation, all nations face significant hurdles.
The high demand for the product in this region has been largely ascribed to the region's robust research, commercial basis, and the significant number of clinical trials being conducted for T-cell treatments. The adoption of these therapies has also been hastened, leading to significant market growth due to the rising number of approvals from regulators in Canada and the US, as well as the region's shifting reimbursement environment. Additionally, the rising prevalence of chronic illnesses like cancer and autoimmune diseases and the presence of well-established and powerful market competitors are the main factors for intensive R&D in this region. Thus, the market in North America is anticipated to grow throughout the forecast period due to an increase in cancer incidence and the expansion of clinical trials in T-Cell therapies.
The US market dominated the North America T-Cell therapy Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $2,375.5 million by 2030. The Canada market is poised to grow at a CAGR of 18.8% during (2023-2030). Additionally, The Mexico market should witness a CAGR of 17.7% during (2023-2030).
Based on End-user, the market is segmented into Hospitals and Cancer Treatment Centers. Based on Indication, the market is segmented into Lymphoma, Acute Lymphocytic Leukemia and Others. Based on Therapy Type, the market is segmented into CAR T-Cell Therapy (Axicabtagene Ciloleucel, Tisagenlecleucel, Brexucabtagene Autoleucel and Others) and T-Cell Receptor (TCR)-Based. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Merck KGaA, Johnson & Johnson, AbbVie, Inc., Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Sorrento Therapeutics, Inc., Bristol Myers Squibb Company, Immunocore Holdings plc and Pfizer, Inc.
Scope of the Study
By End-user
- Hospitals
- Cancer Treatment Centers
By Indication
- Lymphoma
- Acute Lymphocytic Leukemia
- Others
By Therapy Type
- CAR T-Cell Therapy
- Axicabtagene Ciloleucel
- Tisagenlecleucel
- Brexucabtagene Autoleucel
- Others
- T-Cell Receptor (TCR)-Based
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Merck KGaA
- Johnson & Johnson
- AbbVie, Inc.
- Gilead Sciences, Inc.
- Amgen, Inc.
- Novartis AG
- Sorrento Therapeutics, Inc.
- Bristol Myers Squibb Company
- Immunocore Holdings plc
- Pfizer, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. Competition Analysis - Global
Chapter 4. North America T-Cell therapy Market by End User
Chapter 5. North America T-Cell therapy Market by Indication
Chapter 6. North America T-Cell therapy Market by Therapy Type
Chapter 7. North America T-Cell therapy Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Merck KGaA
- Johnson & Johnson
- AbbVie, Inc.
- Gilead Sciences, Inc.
- Amgen, Inc.
- Novartis AG
- Sorrento Therapeutics, Inc.
- Bristol Myers Squibb Company
- Immunocore Holdings plc
- Pfizer, Inc.
Methodology
LOADING...
